Perrigo Moves Closer To Exclusive Consumer Focus With UK Rx Generics Business Sale
Executive Summary
Perrigo’s ambitions to become a consumer-focused company are a step closer after the firm announced an immediate sale of a ‘non-core’ asset.
You may also be interested in...
Perrigo’s Consumer E-commerce Sales Jump 142% In US, Improve Pan-European Marketing Potential
While e-commerce is about 8% of Perrigo’s total sales, it increased 142% for its Americas consumer business and by “the high 40s” for its European consumer business, which online sales could change from “a string of pearls, a lot of regional brands” to product lines that sell across multiple countries.
Perrigo’s Pending OTC Launches Promising But Pandemic Precludes Pumping Guidance
A diclofenac topical analgesic is first, likely followed by a line extension for its Prevacid 24HR PPI brand. Perrigo also plans to introduce natural-based products that “leverage our expertise in Europe."
Perrigo Takes $50M Step For US Consumer Health Industry Into CBD, Invests In Supplier Kazmira
Perrigo leads major consumer health companies into the CBD space with its $50m investment in Kazmira LLC, a Colorado business. The firm says the companies will lay groundwork for quality standards in the CBD market.